Related Experiment Video

Updated: Mar 29, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress

Gerald S Falchook1, Christel C Bastida2, Razelle Kurzrock3

  • 1Sarah Cannon Research Institute at HealthONE, Denver, CO.

Seminars in Oncology
|November 29, 2015
PubMed

Insights

Aurora kinase inhibitors target mitotic events crucial for cancer cell division. Clinical trials show promising anti-tumor activity in advanced cancers, despite notable side effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Aurora kinases (A, B, C) regulate mitosis and are implicated in cancer development.
  • Aurora A and B are validated anticancer targets due to their role in tumorigenesis.
  • Inhibitors targeting Aurora kinases have advanced to clinical trials for cancer treatment.

Purpose of the Study:

  • To review the biological rationale for targeting Aurora kinases in cancer.
  • To summarize clinical trials of Aurora kinase inhibitors, focusing on early-phase studies.
  • To highlight the anti-tumor activity and side effect profiles of these agents.

Main Methods:

  • Literature review of preclinical and clinical studies on Aurora kinase inhibitors.
  • Analysis of data from early-phase clinical trials, including safety and efficacy endpoints.
  • Synthesis of information on the biological roles of Aurora kinases in cell division and cancer.

Main Results:

  • Several Aurora A, B, and pan-Aurora kinase inhibitors have entered clinical development.
  • Observed anti-tumor responses, including complete remissions, in advanced malignancies like ovarian cancer and acute myelogenous leukemia.
  • Common side effects include febrile neutropenia, stomatitis, gastrointestinal toxicity, hypertension, and fatigue.

Conclusions:

  • Aurora kinase inhibitors represent a promising therapeutic strategy for various advanced cancers.
  • Further clinical investigation is warranted to optimize the use of these agents and manage their toxicities.
  • Targeting Aurora kinases offers a viable approach to disrupting cancer cell proliferation.

More Related Videos

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

3.6K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K